| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system t...
Novo Nordisk CEO defends the high U.S. prices of Ozempic and Wegovy, arguing that the drugs reduce obesity-related costs. Senat...
Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite co...
Sesame introduces an affordable weight loss program with compounded versions of Wegovy amid supply shortages. The program provi...
Novo Nordisk and Eli Lilly are competing for the obesity-drug market, but their growth plans extend beyond weight-loss treatmen...
A recent study in JAMA Network Open raises concerns about a potential link between GLP-1 drugs Ozempic and Wegovy and an increa...
Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently di...
